AMWatch

William Demant Invest i stor satsning på kræftdiagnostik

Oticonfondens investeringsarm, William Demant Invest, køber 85 pct. af aktierne i et stort internationalt medico-selskab, der leverer udstyr til kræftdiagnostik. ”I vores sammenhæng er der tale om et signifikant opkøb,” lyder det fra den adm. direktør Niels Jacobsen.

Niels Jacobsen, adm. direktør i William Demant Invest

Det danske investeringsselskab William Demant Invest, 100 pct. ejet af Oticon Fonden, som sidder på aktiemajoriteten i høreappartskoncernen William Demant, har netop offentliggjort købet af den engelske og internationale virksomhed Vision RT, som udvikler produkter til strålebehandling af kræftsvulster.

William Demant Invest overtager ca. 85 pct. af virksomheden, hvis tre stiftere fortsætter med en ejerandel.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from AMWatch

Norway has the fastest growing investment fund market in Europe

So far in 2021, Norway has experienced massive inflows to its investment fund markets, beating former records. The pandemic and different government initiatives have resulted in an increased savings rate. Data also show that market shares are shifting among Norwegian fund managers.

Latest news

Jobs

Latest news from FinansWatch (dk)

Latest news from EnergyWatch

Latest news from ShippingWatch